| 李志坚 李哲 卢强 王艳 王伟锋 祖超.CA19-9、CA125、CEA 及Ferritin 联合检测诊断非小细胞肺癌脑、骨转移
的临床价值研究[J].,2014,14(19):3729-3732 |
| CA19-9、CA125、CEA 及Ferritin 联合检测诊断非小细胞肺癌脑、骨转移
的临床价值研究 |
| Clinical significance of Combined Detection of CA19-9, CA125, CEA andFerritin in the Diagnosis of NSCLC with Brain or Bone Metastasis |
| |
| DOI： |
| 中文关键词: 非小细胞肺癌 肿瘤标志物 脑转移 骨转移 |
| 英文关键词: Non-small cell lung cancer Tumor markers Brain metastasis Bone metastasis |
| 基金项目:陕西省自然科学基金项目（2012JM4022） |
|
| 摘要点击次数: 668 |
| 全文下载次数: 1053 |
| 中文摘要: |
| 目的：研究CA19-9、CA125、癌胚抗原(CEA)以及铁蛋白(Ferritin)四种肿瘤标志物联合检测用于诊断非小细胞肺癌(NSCLC)
脑或(和)骨转移的临床价值。方法：选取2011 年5 月至2012 年5 月于我院就诊的NSCLC 患者184 例。将发现脑或(和)骨转移者
归为转移组，共96例；将未发现脑、骨转移者归为无转移组，共88 例，采用电化学发光免疫分析法测定各组患者血清中CA19-9、
CA125、CEA以及Ferritin的水平，探讨其在NSCLC患者脑或(和)骨转移中的诊断效能。结果：在发生脑或(和)骨转移的NSCLC
患者中，CA19-9、CA125、CEA及Ferritin 四种肿瘤标志物的水平和阳性率均显著高于未发生骨、脑转移的患者。ROC 曲线分析显
示，以上四种肿瘤标志物对诊断NSCLC 骨或(和)脑转移的敏感度分别为73.48 %、69.13 %、66.35 %和61.34 %；特异度分别为
80.02 %、32.51%、65.11 %和62.58 %；将四种肿瘤标志物联合进行诊断的敏感度和特异度分别为91.21%和88.64%，显著高于单
一标志物诊断。结论：发生脑或(和)骨转移的NSCLC 患者血清中CA19-9、CA125、CEA 以及Ferritin 四种肿瘤标志物水平均显著
升高，以上标志物联合检测可提高NSCLC 患者脑或(和)骨转移的诊断效能，可作为早期诊断NSCLC 患者脑或(和)骨转移的辅助
检测指标。 |
| 英文摘要: |
| Objective:To explore the clinical value of combined detection of CA19-9, CA125, CEA and Ferritin in the diagnosis
of non-small cell lung cancer (NSCLC) with brain, bone metastasis.Methods:184 patients who were diagnosed as non-small cell lung
cancer form May 2011 to May 2012 in our hospital were selected. The patients were categorized into two groups according to the
metastasis status, patients who were diagnosed with bone or(and) brain metastasis were allocated to the metastasis group(96 cases), others
were allocated to the non-metastasis group (88 cases). The serum CA19-9, CA125, CEA and Ferritin levels were measured by
electrochemiluminescence immunoassay. The power of test of all tumor markers and combined detection were calculated and compared.Results:The levels of serum CA19-9, CA125, CEA and Ferritin were all significantly higher in the metastasis group than those of the
non-metastasis group. The sensitivities of the tumor markers mentioned above for bone or (and) brain metastasis were 73.48 %, 69.13 %,
66.35 %and 61.34 %, respectively; while the specificities were 80.02 %, 32.51%, 65.11 %and 62.58 %, respectively. The sensitive and
specificity of combined detection were 91.21%and 88.64%, which were much higher than those of the single detection.Conclusion:The
levels of serum CA19-9, CA125, CEA and Ferritin were significantly increased in NSCLC patients with bone or (and) brain metastasis;
combined detection of CA19-9, CA125, CEA and Ferritin could increase the power of test in the diagnosis of NSCLC with bone or(and)
brain metastasis. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
